First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia
Phase 2 study to assess efficacy and safety of once daily linperlisib in patients with advanced peripheral T/NK cell lymphoma
Opdivo-based treatments are now approved for five indications in upper gastroesophageal cancers
Dr. Shah will lead strategic and operational clinical development of the company's diverse pipeline
Despite advances over the past 20 years, ovarian cancer treatment requires better standard of care
With the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced breast cancer in the first-line (1L) setting
Subscribe To Our Newsletter & Stay Updated
